Skip to main content
CRS 2025 Annual Meeting & Exposition Main banner
Final Program


CRS Abstract Guide
Rate Poster

Nanomedicine and Nanoscale Delivery (Focus Group - NND)

(304) Targeted mRNA delivery to metastatic tumors using functionalized nanoparticles

Introduction: Cancer immunotherapy faces challenges in treating metastases and solid tumors, particularly due to the lack of specific cell surface targets, which limits tumor eradication without harming healthy tissues1. Claudin 6 (CLDN6) has been identified as a potential target2, and the immune cytokine tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) shows promise as a cancer-specific therapy3. Here, we developed a lipid nanoparticle (LNP) platform functionalized with anti-CLDN6 antibodies to deliver TRAIL mRNA to colon cancer cells, aiming to enhance targeted treatment.

Learning Objectives:

  • Functionalizing LNPs with anti-CLDN6 antibodies improves TRAIL mRNA delivery to metastatic tumors.
  • Our LNP platform delivers mRNA specifically to tumor cells, enhancing immunotherapy efficacy.
  • TRAIL-LNP with anti-CLDN6 functionalization significantly inhibits colon cancer progression.
Walison da Silva – Graduate student, Physiology and Biophysics, Federal University of Minas Gerais; Pedro Dias – Pos-doc, Physiology and Biophysics, Federal University of Minas Gerais; Kelly Bicalho – Researcher, René Rachou Institute; Vivian Costa – Professor, Morphology, Federal University of Minas Gerais; Mauro Teixeira – Professor, Immunology, Federal University of Minas Gerais